Veterans Health Administration: Implementation of pharmacogenomic clinical decision support with statin medications and the SLCO1B1 gene as an exemplar.
Kelly M TomcsanyiKelvin A TranJill BatesFrancesca E CunninghamRobert SilvermanAmy K NorrisVon R MooreDeepak VooraPublished in: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2023)
The VHA PHASER program identifies and addresses drug-gene interactions as an application of precision medicine to reduce veterans' risks for adverse events. The PHASER program's implementation of statin pharmacogenomics utilizes a patient's SCLO1B1 phenotype to alert providers of the risk for SAMS with the statin being prescribed and how to lower that risk through a lower dose or alternative statin selection. The PHASER program may help reduce the number of veterans who experience SAMS and may improve their adherence to statin medications.
Keyphrases
- clinical decision support
- quality improvement
- cardiovascular disease
- coronary artery disease
- healthcare
- electronic health record
- genome wide
- low density lipoprotein
- primary care
- public health
- copy number
- mental health
- type diabetes
- emergency department
- gene expression
- adverse drug
- risk assessment
- health promotion
- health information